Rituximab-Abbs

Truxima

CD20-directed Cytolytic Antibody

NADAC/unit N/A

No Shortage

Rituximab-Abbs targets CD20-positive cells to treat certain lymphomas and autoimmune conditions.

Covered Lives

Explore in the Ecosystem

rxsaver.aiCompare prices for Rituximab-Abbs drfinder.aiFind doctors who prescribe Rituximab-Abbs rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Rituximab-Abbs

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.